

Table 4. Summary of Natural History Study Mechanistic Samples for Participants that develop T1D at some point over Baseline or Follow-up
 (Complete Collection/Visit Hx Required*)
 P2 (n=91); P3:6m (n=39); P3:12m (n=18); P3:18m (n=8) P3:24m (n=4); P3:30m (n=4); P3:36m (n=2)

Collection Phase*	Sample Type**	No. Subjects (% Row Total): <25%	No. Subjects (% Row Total): 25-50%	No. Subjects (% Row Total): >=25%	No. Subjects (% Row Total): >=50%	Risk Missing or TBD	Total No. Subjects Submitting Sample
Baseline	DNA	. (.)	2 (3.6)	. (.)	43 (76.8)	11 (19.6)	56
	HLA	3 (3.4)	2 (2.3)	. (.)	70 (79.5)	13 (14.8)	88
	RNA	1 (2.2)	2 (4.3)	. (.)	32 (69.6)	11 (23.9)	46
	PLASMA	. (.)	2 (4.8)	. (.)	29 (69.0)	11 (26.2)	42
	SERUM	1 (2.4)	2 (4.8)	. (.)	29 (69.0)	10 (23.8)	42
	PBMC	. (.)	2 (4.8)	. (.)	29 (69.0)	11 (26.2)	42
Follow-up (6m)	RNA	1 (4.8)	2 (9.5)	. (.)	17 (81.0)	1 (4.8)	21
	PLASMA	1 (5.0)	2 (10.0)	. (.)	16 (80.0)	1 (5.0)	20
	SERUM	1 (5.3)	2 (10.5)	. (.)	15 (78.9)	1 (5.3)	19
	PBMC	1 (5.3)	2 (10.5)	. (.)	15 (78.9)	1 (5.3)	19
Follow-up (12m)	RNA	1 (10.0)	2 (20.0)	. (.)	7 (70.0)	. (.)	10
	PLASMA	1 (9.1)	2 (18.2)	. (.)	8 (72.7)	. (.)	11
	SERUM	1 (9.1)	2 (18.2)	. (.)	8 (72.7)	. (.)	11
	PBMC	1 (9.1)	2 (18.2)	. (.)	8 (72.7)	. (.)	11
Follow-up (18m)	RNA	. (.)	1 (16.7)	. (.)	5 (83.3)	. (.)	6
	PLASMA	. (.)	1 (20.0)	. (.)	4 (80.0)	. (.)	5
	SERUM	. (.)	1 (20.0)	. (.)	4 (80.0)	. (.)	5
	PBMC	. (.)	1 (25.0)	. (.)	3 (75.0)	. (.)	4
Follow-up (24m)	RNA	. (.)	1 (25.0)	. (.)	3 (75.0)	. (.)	4
	PLASMA	. (.)	1 (25.0)	. (.)	3 (75.0)	. (.)	4
	SERUM	. (.)	1 (33.3)	. (.)	2 (66.7)	. (.)	3
	PBMC	. (.)	1 (25.0)	. (.)	3 (75.0)	. (.)	4
Follow-up (30m)	RNA	. (.)	1 (33.3)	. (.)	2 (66.7)	. (.)	3
	PLASMA	. (.)	1 (33.3)	. (.)	2 (66.7)	. (.)	3
	SERUM	. (.)	1 (33.3)	. (.)	2 (66.7)	. (.)	3
	PBMC	. (.)	1 (33.3)	. (.)	2 (66.7)	. (.)	3
Follow-up (36m)	RNA	. (.)	1 (50.0)	. (.)	1 (50.0)	. (.)	2
	PLASMA	. (.)	1 (50.0)	. (.)	1 (50.0)	. (.)	2
	SERUM	. (.)	1 (50.0)	. (.)	1 (50.0)	. (.)	2
	PBMC	. (.)	1 (50.0)	. (.)	1 (50.0)	. (.)	2

* A subject enumerated in any Phase 3 visit is required to have had a Baseline (Phase 2) visit, as well as have completed "all" P3 visits preceding their latest P3 visit.

** All DNA samples collected -- across all visits herein (Baseline and any Phase 3 follow-up) -- are presented at Baseline. Note that a subject should have only provided one DNA sample, although it is possible multiple were provided.